Endogenous ligand of the NK activating receptor NKp46
NK 激活受体 NKp46 的内源性配体
基本信息
- 批准号:10116279
- 负责人:
- 金额:$ 22.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:AffectAftercareAllogenicAntineoplastic AgentsApoptosisAutologousBindingBinding ProteinsBlocking AntibodiesCD8-Positive T-LymphocytesCell CommunicationCell LineCell surfaceCellsCellular StressChemotherapy-Oncologic ProcedureChimeric ProteinsCross-PrimingDataDendritic CellsDependenceDown-RegulationEatingEndoplasmic ReticulumEquilibriumFlavivirusFusobacterium InfectionsGenesHumanImmuneImmune responseImmunityImmunologic SurveillanceImpairmentIncubatedInfectionInfiltrationInfluenza A virusInfluenza HemagglutininKnock-outKnowledgeLigandsLinkLymphocyteMalignant NeoplasmsMammalsManuscriptsMediatingMediator of activation proteinMetapneumovirusMusNK Cell ActivationNatural Killer CellsPhagocytesPharmaceutical PreparationsPlayPregnancyPreparationProductionProteinsRadiation therapyReceptor CellRecombinantsReovirus InfectionsRoleSialic AcidsSignal TransductionStressSurface Plasmon ResonanceTestingTherapeuticTumor Cell LineViralWorkZIKV infectionZika Virusbasebiophysical techniquescalreticulincancer cellcell killingchemotherapeutic agentchemotherapycytokinecytotoxicityendoplasmic reticulum stressfetalfetus cellfirst respondergenetic manipulationgraft vs host diseaseimmunogenic cell deathimmunological synapseimmunological synapse formationin vivoinhibitor/antagonistknock-downmouse modelneoplastic celloverexpressionreceptorresponsetooltrophoblasttumortumor growthvirtual
项目摘要
Natural killer cells (NK) act as a first line of defense against infection and cancer. NK activation is controlled by
a balance of signals transmitted by activating and inhibitory NK receptors. The activating receptor NKp46 is
considered the major activating receptor in natural cytotoxicity against autologous, allogeneic and xenogeneic
target cells. NKp46 is conserved in mammals and virtually ubiquitously expressed on NK, suggesting it is
functionally important. Mice deficient in Ncr1, the gene encoding NKp46, are impaired in tumor immune
surveillance, have more severe influenza A, metapneumovirus, reovirus and fusobacterium infections and graft
versus host disease. The endogenous ligand of this important activating NK receptor is not known, despite
decades of searching. Our preliminary work suggests that NKp46 recognizes calreticulin (CRT), which is
normally found inside the endoplasmic reticulum (ER) but gets transferred to the cell surface in ER-stressed cells
or tumor cells treated with some cancer drugs. An NKp46-Ig fusion protein specifically pulls down cell-surface
CRT (ecto-CRT) and preliminary data using surface plasmon resonance indicate specific binding. Knocking
down CALR, the gene encoding for CRT, or adding blocking antibodies to CRT inhibits NKp46-mediated NK
killing. Some chemotherapeutic agents and radiotherapy induce an immunostimulatory type of programmed cell
death in cancer cells, known as immunogenic cell death (ICD), which removes surviving tumor cells after
treatment. The mechanism behind ICD has been linked to ecto-CRT, which serves as an “eat me”/phagocytic
signal for dendritic cells, which then activate anti-tumor CD8+ T cells by cross-priming. Here we hypothesize that
NKp46 recognizes ecto-CRT, and that NK recognition of ER-stressed cells via NKp46 interaction with ecto-CRT
plays an important role in ICD and NK-mediated immune defense more generally. In preliminary data, infection
with ZIKV, which replicates in the ER and causes ER stress, and treatment of tumor cell lines with ICD-inducing
chemotherapy drugs induces ecto-CRT and NKp46-dependent NK killing. Moreover, CRT-coated tumor cells
become NK cell targets, and NCR1 knockout in an NK cell line strongly inhibits its killing of targets with exposed
CRT. To test our hypotheses, we will first confirm that ecto-CRT is a ligand for NKp46 by using biophysical
methods to characterize ecto-CRT and NKp46 binding and identifying the regions of CRT responsible for the
interaction. Genetic manipulation or blocking of NKp46 on NK and of ecto-CRT on tumor targets will examine
the role of this receptor-ligand interaction in NK recognition, immune synapse formation and functional responses
to infected and tumor cells. NK killing of untreated tumor cells and tumor cells treated with ICD-inducing and
noninducing drugs will be compared. The in vivo role of NKp46 in controlling ZIKV infection and mouse tumors
(without and with chemotherapy) will be assessed by comparing viral levels and tumor growth, NK cell infiltration
of tumors and survival in wild-type and Ncr1-/- mice.
自然杀伤细胞(NK)是抵抗感染和癌症的第一道防线。
通过活化和抑制NK受体传递的信号的平衡。活化受体NKp 46是
被认为是针对自体、同种异体和异种的天然细胞毒性中的主要活化受体。
NKp 46在哺乳动物中是保守的,并且实际上在NK细胞上普遍表达,这表明它是靶细胞。
Ncr 1(编码NKp 46的基因)缺陷的小鼠在肿瘤免疫中受损,
监测,有较严重的甲型流感,偏肺病毒,呼肠孤病毒和梭杆菌感染和移植
这种重要的活化NK受体的内源性配体是未知的,尽管
我们的初步工作表明,NKp 46识别钙网蛋白(CRT),这是一种
通常存在于内质网(ER)内,但在ER-1应激细胞中转移到细胞表面
一种NKp 46-β IG融合蛋白特异性地拉低细胞表面的蛋白质,
CRT(体外CRT)和使用表面等离子体共振的初步数据表明特异性结合。
下调CRT编码基因CALR或在CRT上添加阻断抗体可抑制NKp 46介导的NK细胞
一些化疗药物和放疗诱导免疫刺激型的程序化细胞
癌细胞死亡,称为免疫原性细胞死亡(ICD),它会在癌细胞死亡后清除存活的肿瘤细胞。
ICD背后的机制与体外循环CRT有关,其充当“吃我”/吞噬细胞,
树突状细胞的信号,然后通过交叉免疫激活抗肿瘤CD 8 + T细胞。
NKp 46识别外膜CRT,并且NK通过NKp 46与外膜CRT的相互作用识别ER-CRT应激细胞,
在ICD和NK细胞介导的免疫防御中起重要作用。
用ZIKV(其在ER中复制并引起ER应激)处理肿瘤细胞系,以及用ICD-GFP诱导的肿瘤细胞系处理肿瘤细胞系。
化疗药物可诱导体外CRT和NKp 46-NK依赖性NK杀伤,而且,CRT-CRT包被的肿瘤细胞
成为NK细胞靶标,并且NK细胞系中的NCR 1敲除强烈抑制其对暴露于NCR 1的靶标的杀伤。
为了验证我们的假设,我们将首先通过使用生物物理方法证实外膜CRT是NKp 46的配体。
表征外膜CRT和NKp 46结合的方法,以及鉴定CRT中负责NKp 46结合的区域的方法。
基因操作或阻断NK细胞上的NKp 46和肿瘤靶点上的外显CRT将检查
这种受体-配体相互作用在NK识别、免疫突触形成和功能反应中作用
未处理的肿瘤细胞和用ICD-10诱导和治疗的肿瘤细胞的NK杀伤
NKp 46在控制ZIKV感染和小鼠肿瘤中的体内作用
将通过比较病毒水平和肿瘤生长、NK细胞浸润(无和有化疗)来评估
在野生型和Ncr 1-nc/-nc小鼠中的肿瘤和存活率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Judy Lieberman其他文献
Judy Lieberman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Judy Lieberman', 18)}}的其他基金
Tumor-targeted disruption of mismatch repair in microsatellite stable colorectal cancer
微卫星稳定结直肠癌中错配修复的肿瘤靶向破坏
- 批准号:
10578049 - 财政年份:2022
- 资助金额:
$ 22.13万 - 项目类别:
Mechanistic elucidation of inflammasome assembly and regulation. Supplement: Testing drugs that curtail inflammasome activation to suppress SARS-CoV-2 pathogenesis
炎症小体组装和调节的机制阐明。
- 批准号:
10159600 - 财政年份:2020
- 资助金额:
$ 22.13万 - 项目类别:
Granulysin, Granzymes and Perforin in Bacterial Immune Defense
细菌免疫防御中的颗粒溶素、颗粒酶和穿孔素
- 批准号:
9222706 - 财政年份:2016
- 资助金额:
$ 22.13万 - 项目类别:
Control of placental infection by decidual NK cell secreted granulysin
蜕膜NK细胞分泌颗粒溶素控制胎盘感染
- 批准号:
9236206 - 财政年份:2016
- 资助金额:
$ 22.13万 - 项目类别:
Control of placental infection by decidual NK cell secreted granulysin
蜕膜NK细胞分泌颗粒溶素控制胎盘感染
- 批准号:
9092639 - 财政年份:2016
- 资助金额:
$ 22.13万 - 项目类别:
相似海外基金
Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
- 批准号:
DP240100640 - 财政年份:2024
- 资助金额:
$ 22.13万 - 项目类别:
Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
- 批准号:
23K01889 - 财政年份:2023
- 资助金额:
$ 22.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10452217 - 财政年份:2022
- 资助金额:
$ 22.13万 - 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10670838 - 财政年份:2022
- 资助金额:
$ 22.13万 - 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
- 批准号:
DP200100492 - 财政年份:2020
- 资助金额:
$ 22.13万 - 项目类别:
Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
- 批准号:
407264 - 财政年份:2019
- 资助金额:
$ 22.13万 - 项目类别:
Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
- 批准号:
18K18240 - 财政年份:2018
- 资助金额:
$ 22.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
- 批准号:
17K12379 - 财政年份:2017
- 资助金额:
$ 22.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
- 批准号:
17K13937 - 财政年份:2017
- 资助金额:
$ 22.13万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
- 批准号:
8742767 - 财政年份:2014
- 资助金额:
$ 22.13万 - 项目类别: